NasdaqCM:RGCPharmaceuticals
Regencell Bioscience Holdings (RGC) Is Down 6.3% After DOJ Probe Spurs Class Actions Over Valuation Narrative
In recent months, multiple law firms have filed securities class action lawsuits against Regencell Bioscience Holdings and certain officers, following the company’s earlier disclosure of a U.S. Department of Justice subpoena related to trading in its ordinary shares and broader corporate matters.
The complaints highlight an unusual contrast between Regencell’s very small research budget, lack of revenue and products, and a multibillion‑dollar market value, raising sharp questions about how...